Regarding a macrophage-mediated anti-tumor immunotherapy strategy based on gene-edited nanoparticles: the first step involves blocking the CD47-SIRPα pathway, and the second step is to repolarize tumor-associated macrophages (98). The gene discussed is CD47; the disease is neoplasm.